Ellen Rose
Head of Communications
Replay available
Prothena Corporation plc (NASDAQ: PRTA) Q4 2020 earnings conference call, held 2021-02-11. Replay captured from the company's public earnings webcast.

Head of Communications
President & Chief Executive Officer
Chief Operating Officer & Chief Financial Officer
Chief Scientific Officer
Chief Development Officer
Analyst (Oppenheimer)
Analyst (Jefferies)
Analyst (Cantor Fitzgerald)
Analyst (BTIG)
Analyst (RBC Capital Markets)
Analyst (Bank of America)
Ladies and gentlemen, thank you for standing by and welcome to the Procena fourth quarter and full year 2020 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star then one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star then zero. I would now like to hand the conference over to one of your speakers today, Ellen Rose, Head of Communications. Please go ahead. Thank you, Michelle. Good morning, everyone, and welcome to Perthena's Investor Conference Call to review our business progress and our fourth quarter and full year 2020 financial results and our 2021 financial guidance. Please review the press release we issued earlier today, which is available on our website at perthena.com and is also attached to a Form 8K filed today with the SEC. On today's call, Dr. Jean Kinney, our President and Chief Executive Officer, will highlight Perthena's recent and 2020 pipeline progress, what distinguishes our scientific platform and our path for sustainable growth. Following Jean's comments, Tran Nguyen, our Chief Operating Officer and Chief Financial Officer, will review our financial results and performance for the fourth quarter and full year of 2020 and 2021 financial guidance. Jean will then provide an overview of our near-term milestones. We will then open the call for Q&A and be joined by Dr. Wagner-Zago, our Chief Scientific Officer, and Dr. Radhika Triparaneni, our Chief Development Officer. Before we begin, I would like to remind you that during the course of today's presentation, we will be making for...